Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 39 of 41.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    EudraCT Number: 2017-004881-85 Sponsor Protocol Number: PSMA-POLM Start Date*: 2020-12-02
    Sponsor Name:AZIENDA OSPEDALIERA SANT'ANDREA
    Full Title: PET-CT with 68Ga-PSMA as a marker of neoangiogenesis in lung adenocarcinoma
    Medical condition: Lung adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005106-35 Sponsor Protocol Number: INTRUST Start Date*: 2018-12-21
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: PHASE I - II STUDY OF INTRATUMORAL URELUMAB COMBINED WITH NIVOLUMAB IN PATIENTS WITH SOLID TUMORS
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-002767-98 Sponsor Protocol Number: UCDCRC/19/01 Start Date*: 2020-05-28
    Sponsor Name:University College Dublin
    Full Title: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC)
    Medical condition: Patients with Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002223-42 Sponsor Protocol Number: A4091061 Start Date*: 2015-10-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER ...
    Medical condition: Metastatic Bone Pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) SK (Completed) HU (Completed) RO (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001860-12 Sponsor Protocol Number: CMAK683X2101 Start Date*: 2017-01-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
    Medical condition: Advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003971-19 Sponsor Protocol Number: RP-01 Start Date*: 2006-01-24
    Sponsor Name:MEDA AB [...]
    1. MEDA AB
    2.
    Full Title: Clinical study to evaluate the ability of MUSE to increase erectile function in post-radical prostatectomy patients - Randomised, controlled, open study with two parallel groups comparing MUSE 250...
    Medical condition: Erectile Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    10061461
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002641-29 Sponsor Protocol Number: INCB57643-101 Start Date*: 2018-03-20
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
    Medical condition: Subjects with relapsed or refractory advanced or metastatic malignancies.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001443-27 Sponsor Protocol Number: CA209-6E8,CNN-BC Start Date*: 2021-11-02
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after maximal tumor resection in non-metastatic muscle invasive Bladder Cancer. (CA209-6E8, C...
    Medical condition: Patients with non-metastatic muscle invasive bladder cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066753 Bladder transitional cell carcinoma stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-006515-76 Sponsor Protocol Number: REO 011 Start Date*: 2007-01-08
    Sponsor Name:Oncolytics Biotech Inc
    Full Title: A Dose Targeted Phase I/II Study To Evaluate The Feasibility, Safety, And Biological Effects Of Intravenous Administration of A Wild-Type Reovirus (REOLYSIN®) in Combination With Paclitaxel and Car...
    Medical condition: Advanced or metastatic solid tumours that are refractory to standard therapy or for which no curative standard therapy exists and for which paclitaxel plus carboplatin is appropriate palliative che...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000625-12 Sponsor Protocol Number: CTMX-M-2009-001 Start Date*: 2018-02-15
    Sponsor Name:CytomX Therapeutics, Inc
    Full Title: A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Lo...
    Medical condition: Metastatic or locally advanced unresectable solid tumors in following indications: breast cancer (BC), castrate-resistant prostate carcinoma (CRPC), non-small cell lung carcinoma (NSCLC), ovarian...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007942-36 Sponsor Protocol Number: EFC6520 Start Date*: 2008-09-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major A...
    Medical condition: The subjects who will participate to this clinical trial are patients undergoing major abdominal surgery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) LV (Completed) EE (Completed) DK (Completed) BE (Completed) SE (Completed) HU (Completed) CZ (Completed) LT (Completed) SI (Completed) IT (Completed) SK (Completed) BG (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002298-11 Sponsor Protocol Number: NO21895 Start Date*: 2008-11-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patient...
    Medical condition: To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002770-27 Sponsor Protocol Number: DRA-104-001 Start Date*: 2021-07-12
    Sponsor Name:Dracen Pharmaceuticals, Inc.
    Full Title: Phase 1 and phase 2a, first-in-human study of DRP-104, a glutamine antagonist, in adult patients with advanced solid tumors
    Medical condition: Cancer, advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004444-38 Sponsor Protocol Number: GAIN/GEM/CIS Start Date*: 2019-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det...
    Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028982 Neoplasm biliary tract LLT
    20.0 10042613 - Surgical and medical procedures 10004675 Biliary tract and gallbladder therapeutic procedures HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    21.1 10042613 - Surgical and medical procedures 10061962 Gallbladder operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003352-20 Sponsor Protocol Number: BO40729 Start Date*: 2019-04-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B)
    Medical condition: Advanced Malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) DK (Completed) PL (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) HU (Trial now transitioned) NO (Prematurely Ended) GR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Completed) CZ (Trial now transitioned) RO (Trial now transitioned) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003371-34 Sponsor Protocol Number: CDI-CS-002 Start Date*: 2015-02-20
    Sponsor Name:Basilea Pharmaceutica International Ltd.
    Full Title: An open-label Phase 1/2a study of oral BAL101553 in adult patients with advanced solid tumors and in adult patients with recurrent or progressive glioblastoma or high-grade glioma
    Medical condition: Advanced or recurrent solid tumors, recurrent or progressive glioblastoma, or high-grade glioma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000038-33 Sponsor Protocol Number: DF6002-001 Start Date*: 2021-08-25
    Sponsor Name:Dragonfly Therapeutics, Inc.
    Full Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monoth...
    Medical condition: Solid Tumor Melanoma NSCLC Triple-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001879-37 Sponsor Protocol Number: GB1275-1101(KEYNOTE-A36) Start Date*: 2020-01-14
    Sponsor Name:GB006, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.
    Full Title: A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination...
    Medical condition: Phase 1: Advanced solid tumors, metastatic pancreatic adenocarcinoma Phase 2: Specified metastatic solid tumors
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-002626-86 Sponsor Protocol Number: 29BRC20.0159 Start Date*: 2020-07-30
    Sponsor Name:CHRU de Brest
    Full Title: A randomized, open-label, controlled phase III trial comparing the pembrolizumab platinum based chemotherapy combination with pembrolizumab monotherapy in first line treatment of non small-cell lun...
    Medical condition: First line, stage IV non small-cell lung cancer (NSCLC) with PD L1 expression on ≥50 % of tumor cells
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004826-32 Sponsor Protocol Number: 3121001 Start Date*: 2016-10-24
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: Safety and pharmacokinetics of ODM-207 in patients with selected advanced solid tumours: an open-label, non-randomised, uncontrolled, multicentre, first-in-human study with cohort expansion
    Medical condition: Advanced Solid Tumours
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 33  34  35  36  37  38  39  40  41  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 04:23:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA